Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Otamixaban

Otamixaban (FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa. IC50 value: Target: Factor Xa Otamixaban is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa. In vivo experiments have demonstrated that Otamixaban is highly efficacious in rodent, canine and porcine models of thrombosis. In addition, recent clinical findings indicate that Otamixaban is efficacious, safe and well tolerated in humans and therefore has considerable potential for the treatment of acute coronary syndrome. This review article chronicles the discovery and pre-clinical data surrounding the fXa inhibitor Otamixaban as well as the recent clinical findings in humans.

Product Specifications

CAS Number

193153-04-7

Product Name Alternative

FXV673

UNSPSC

12352005

Target

Factor Xa

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Otamixaban.html

Purity

98.25

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

N=C(C1=CC=CC(C[C@@H](C(OC)=O)[C@H](NC(C2=CC=C(C=C2)C3=CC=[N+]([O-])C=C3)=O)C)=C1)N

Molecular Formula

C25H26N4O4

Molecular Weight

446.50

References & Citations

[1]Eikelboom JW, Weitz JI.Otamixaban in acute coronary syndromes.Lancet. 2009 Sep 5;374 (9692) :762-4. Epub 2009 Aug 28.|[2]Sabatine MS, Antman EM, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42) : a randomised, double-blind, active-controlled, phase 2 trial.Lancet. 2009 Sep 5;374 (9692) :787-95. Epub 2009 Aug 28.|[3]Guertin KR, Choi YM.The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.Curr Med Chem. 2007;14 (23) :2471-81.|[4]Cohen M, Bhatt DL, et al. SEPIA-PCI Trial Investigators.Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.Circulation. 2007 May 22;115 (20) :2642-51. Epub 2007 May 14.|[5]Guertin, Kevin R.; Choi, Yong-Mi.The discovery of the factor Xa inhibitor Otamixaban: from lead identification to clinical development.Current Medicinal Chemistry (2007), 14 (23), 2471-2481.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Phase 3

Available Sizes

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

Chk1 (CHEK1) pSer280 Rabbit Polyclonal Antibody
AP01552PU-N 100 µg

Chk1 (CHEK1) pSer280 Rabbit Polyclonal Antibody

Sign In for Pricing
View Details
CCDC27 Mouse Monoclonal Antibody [Clone ID: OTI1F8]
CF811190 100 µg

CCDC27 Mouse Monoclonal Antibody [Clone ID: OTI1F8]

Sign In for Pricing
View Details
Recombinant Zinc Alpha 2 Glycoprotein Antibody
RC-6897-01 50 μL

Recombinant Zinc Alpha 2 Glycoprotein Antibody

Sign In for Pricing
View Details
Recombinant Zinc Alpha 2 Glycoprotein Antibody
RC-6897-02 100 µL

Recombinant Zinc Alpha 2 Glycoprotein Antibody

Sign In for Pricing
View Details
Recombinant Zinc Alpha 2 Glycoprotein Antibody
RC-6897-03 1 mL

Recombinant Zinc Alpha 2 Glycoprotein Antibody

Sign In for Pricing
View Details
Frozen Tissue Blocks, Ovary: right
CB524233 1 Block

Frozen Tissue Blocks, Ovary: right

Sign In for Pricing
View Details